Perfusion CT Monitoring to Predict Treatment Efficacy in Renal Cell Carcinoma
NCT ID: NCT01926990
Last Updated: 2022-02-02
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
19 participants
OBSERVATIONAL
2014-08-31
2021-12-17
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
CT Perfusion Imaging in Predicting Treatment Response in Patients With Non-small Cell Lung Cancer or Lung Metastases Treated With Stereotactic Ablative Radiation Therapy
NCT02693080
CT Perfusion Parameters for Advanced HCC Treated by Systemic Immunotherapy
NCT05580809
SPECT/CT for the Characterization of Renal Masses
NCT03996850
Dynamic Perfusion Computed Tomography in Patients With Localized Non-small Cell Lung Cancer
NCT03091816
Evaluation of Novel Cone-Beam CT for Guidance and Adaptation of Precision Radiotherapy
NCT05176860
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
perfusion computed tomography
Undergo perfusion CT
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Treatment planned with sunitinib, pazopanib, sorafenib, bevacizumab, axitinib, nivolumab alone or in combination with an investigational agent
* Ability to understand and willingness to sign a written informed consent document
Exclusion Criteria
* Severe allergy to contrast agent
* Any contraindication for undergoing a CT scan
* Pregnancy or unwillingness to use preventative measures if a woman of child-bearing potential
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Siemens Healthcare QT
INDUSTRY
Stanford University
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Aya Kamaya
Role: PRINCIPAL_INVESTIGATOR
Stanford University Hospitals and Clinics
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Stanford University Cancer Institute
Stanford, California, United States
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
NCI-2013-01626
Identifier Type: REGISTRY
Identifier Source: secondary_id
RENAL0026
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.